Atlas Trials

Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

Clinical trial NCT03308201 · COMPLETED

Trial details

NCT number
NCT03308201
Sponsor
Tianjin Hemay Pharmaceutical Co., Ltd
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Breast Cancer
Start date
2017-10-16
Primary completion
2022-06-30
Enrollment
55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.